| <P style="TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; mso-char-indent-count: 2.0"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">二甲双胍类药物被认为是</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%">Ⅱ</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">型糖尿病治疗的金标准，但在本周的</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">PLoS Medicine</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">上，来自法国的研究人员发表的一项研究表明，同其风险性相比二甲双胍类药物的长期效益并不能肯定。这是一个重要的发现，因为世界上有数以千记的人需要常规服用二甲双胍来帮助控制血糖水平，而他们相信其二甲双胍具有长期健康效益。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial"><BR><SPAN style="mso-spacerun: yes"><FONT face=Arial color=#333333 size=3> </FONT></SPAN></SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">在这项新的研究中，由法国里昂临床研究中心的</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">Catherine Cornu</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">领衔的作者们分析了所有相关的数据，重新评估了二甲双胍对</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%">Ⅱ</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">型糖尿病的利与弊的平衡。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial"><BR><SPAN style="mso-spacerun: yes"><FONT face=Arial color=#333333 size=3> </FONT></SPAN></SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">利用来自</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">13</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">个临床随机对照试验（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">randomized controlled trials</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">，</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">RCT</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">）的大约</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">13000</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">例病人的信息，作者发现同其他药物相比，二甲双胍对由心脑血管疾病和其他原因导致的死亡风险并没有作用。此外，二甲双胍对于心脏病作、中风和心衰等心脑血管病的发生也没有促进作用。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial"><BR><FONT size=3><FONT face=Arial><FONT color=#333333><SPAN style="mso-spacerun: yes"> </SPAN><SPAN style="mso-spacerun: yes"> </SPAN></FONT></FONT></FONT></SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">作者总结说：</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">“</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">我们不能排除任何可能的怀疑，即二甲双胍可能增加或者降低各种原因或者心血管病引起的死亡风险</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">”<BR><SPAN style="mso-spacerun: yes"><FONT face=Arial color=#333333 size=3> </FONT></SPAN></SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">他们解释说：</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">“</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">二甲双胍在预防死亡或者心血管事件上的有效性不能被现在的研究所证实。现行研究的数量和质量并不充分</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">”<BR><SPAN style="mso-spacerun: yes"><FONT face=Arial color=#333333 size=3> </FONT></SPAN></SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">作者们推荐：</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">“</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">为了澄清这些问题需要进一步的研究。评估新的降血糖的药物时，二甲双胍可能是最好的参照药物。但是，二甲双胍是否具有最好风险比（风险</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">/</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">效益比）仍然不清楚。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial">”<BR><SPAN style="mso-spacerun: yes"><FONT face=Arial color=#333333 size=3> </FONT></SPAN></SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">但有一点很重要，那就是对那些服用二甲双胍并有疑虑的患者来说，不应该在没有咨询医生的情况下停药。作者总结说：同其它降糖药相比，二甲双胍可能是危害性最小的药物。它不会导致低血糖、体重增加和心衰。还能降低血栓的患者的死亡风险。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #333333; LINE-HEIGHT: 150%; FONT-FAMILY: Arial"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> |
